Why Is IOVANCE BIOTHERAPEUT (IOVA) Stock Up Today?

IOVA stock surged 13.66% to $7.99 on Thursday, closing in on a new 52-week high. The rally was driven by broader momentum in melanoma-focused biotech stocks following late-stage data from Merck and Moderna on a personalized mRNA cancer vaccine. The positive sentiment spilled over to Iovance Biotherapeutics, which saw strong intraday volume and a sharp upward move from its morning low.

What Happened

The stock opened at $7.03 and climbed steadily throughout the session, reaching a high of $8.05 at 3:30 PM ET. The move followed a string of analyst upgrades and price target increases in recent weeks, including new targets from Mizuho, Barclays, and Citizens. These upgrades came after Iovance reported better-than-expected Q2 results. The stock’s performance also reflected broader market enthusiasm for biotech innovation, particularly in the melanoma space.

The session saw 23.2 million shares traded, more than 1.4 times the 3-month daily average. The stock closed near its session high at $8.02, just below its 52-week high of $7.99. The move built on a recent price trend that saw the stock rise 21.8% over the last eight sessions.

What The Data Shows

The stock has traded between $1.76 and $7.31 over the past 52 weeks. On August 19, it printed 29 fresh 52-week highs and one fresh 52-week low. The company remains unprofitable with a trailing 12-month net margin of -89.1% and an EPS of -0.71. Revenue, however, grew 34.5% TTM. The stock has a market cap of $3.2 billion and a beta of 0.70, indicating lower volatility than the broader market.

What To Watch

Investors should continue to monitor analyst coverage and the broader biotech sector for further momentum. No earnings date is scheduled for the near term, but coverage breadth and sentiment trends will remain key indicators for the stock’s trajectory.